Completed PHASE4 INTERVENTIONAL 2-arm NCT01041092

Double Blind, Placebo-controlled Study of Raloxifene for Negative Symptoms of Schizophrenia in Postmenopausal Women

Double Blind, Placebo-controlled Study of Efficacy, Safety and Tolerance of Raloxifene as an Adjuvant Treatment for Negative Symptoms of Schizophrenia in Postmenopausal Women

Sponsor: Fundació Sant Joan de Déu

Conditions Schizophrenia

Interventions raloxifene

Updated 4 times since 2017 Last updated: Dec 30, 2009 Started: Jun 30, 2004 Primary completion: Dec 31, 2009 Completion: Dec 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01041092, this PHASE4 trial focuses on Schizophrenia and remains completed. Sponsored by Fundació Sant Joan de Déu, it has been updated 4 times since 2004, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jan 2017 — Jan 2021 [monthly]

Completed PHASE4

First recorded

Jun 2004

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fundació Sant Joan de Déu

Data source: Fundació Sant Joan de Déu

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Esplugues de Llobregat, Spain